Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dr Farolfi on Real-World Outcomes With Bevacizumab Plus SOC in Cervical Cancer

August 25th 2025

Alberto Farolfi, MD, PhD, discusses real-world findings with bevacizumab plus platinum-based chemotherapy and pembrolizumab in advanced cervical cancer.

Dr Sarma on the Current Role of Sentinel Node Biopsies in Breast Cancer

August 25th 2025

Deba Sarma, MD, highlights the role of sentinel node biopsies ahead of surgery for the treatment of patients with breast cancer.

Dr Dorritie on the Management of Untreated and Relapsed/Refractory CLL

August 25th 2025

Kathleen A. Dorritie, MD, details the difference in care between the management of untreated CLL and relapsed/refractory CLL.

Evolving Treatment Strategies Reshape the Landscape of Hematologic Malignancies

August 22nd 2025

Naseema Gangat, MBBS, details updates, novel strategies, and factors that inform decision-making in clinical for patients with hematologic malignancies.

Dr Dreyling on the Efficacy of Frontline Acalabrutinib Plus BR in High-Risk MCL

August 21st 2025

Martin Dreyling, MD, PhD, discusses the efficacy of first-line acalabrutinib plus BR in high-risk patients with mantle cell lymphoma.

Dr Shah on Safety and Efficacy Outcomes With Obe-Cel in Older R/R ALL

August 21st 2025

Bijal Shah, MD, MS, discusses key safety and efficacy outcomes from a post hoc analysis of the FELIX trial of obe-cel in relapsed/refractory B-ALL.

Dr Sidana on the Efficacy of Second-Line Cilta-Cel in Relapsed/Refractory Myeloma

August 21st 2025

Surbhi Sidana, MD, discusses the PFS and OS benefit of second-line cilta-cel in patients with relapsed/refractory multiple myeloma.

PARP Inhibitors and Radioligand Therapies Advance Prostate Cancer Care with Biomarker-Driven Strategies

August 21st 2025

Matthew R. Smith, MD, PhD, discusses how PARP inhibition and radioligand therapies are shaping treatment decisions in advanced prostate cancer.

Dr Powles on the Role of the CREST Study in Future Clinical Trial Design in BCG-Naive NMIBC

August 21st 2025

Thomas Powles, MBBS, MRCP, MD, discusses how future clinical trials could leverage the CREST trial as a basis for BCG-naive NMIBC treatment development.

Considerations for Selection and Sequencing in Polycythemia Vera and Myelofibrosis

August 21st 2025

Naseema Gangat, MBBS, delves into the role of ruxolitinib as a standard of care for the treatment of patients with polycythemia vera and myelofibrosis.

Dr Chahoud on the Rationale for Evaluating Zanzalintinib Plus Nivolumab With/Without Relatlimab in ccRCC

August 20th 2025

Jad Chahoud, MD, MPH, discusses the background and rationale for evaluating zanzalintinib plus nivolumab with or without relatlimab in ccRCC.

FDA Approves MMR IHC Panel pharmDx as a Companion Diagnostic for Nivolumab/Ipilimumab in MSI-H/dMMR CRC

August 20th 2025

The FDA has approved the MMR IHC Panel pharmDx to determine eligibility for nivolumab/ipilimumab in patients with MSI-H/dMMR colorectal cancer.

Health Canada Approves Nivolumab Plus Ipilimumab for Unresectable MSI-H/dMMR CRC and Unresectable HCC

August 20th 2025

Nivolumab plus ipilimumab earned approval from Health Canada for select patients with unresectable colorectal cancer and hepatocellular carcinoma.

Novocure Files Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

August 20th 2025

The FDA has received a premarket approval application supported by positive results from the PANOVA-3 trial for Tumor Treating Fields (TTFields)—electric fields that exert physical forces to kill cancer cells via a variety of mechanisms—for locally advanced pancreatic cancer.

Dr Ku on the Rationale for Evaluating JNJ-90014496 in Relapsed/Refractory LBCL

August 19th 2025

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, details the rationale for assessing a dual bispecific CAR T-cell therapy in relapsed/refractory LBCL.

Dr Gangat on Reducing JAK2 Allele Burden With Ruxolitinib or Ropeginterferon Alfa-2b in Polycythemia Vera

August 19th 2025

Naseema Gangat, MBBS, discusses the potential use of ruxolitinib and ropeginterferon alfa-2b-njft to reduce JAK2 allele burden in polycythemia vera.

Magrolimab/Nivolumab Combos Drive Responses in Unresectable Advanced/Recurrent CRC

August 19th 2025

Magrolimab plus nivolumab and FOLFOX with bevacizumab or cetuximab yielded responses in advanced/recurrent colorectal cancer.

Anlotinib Plus Epirubicin Elicits PFS Benefit in Advanced Soft Tissue Sarcoma

August 19th 2025

Anlotinib plus epirubicin conferred a significant PFS benefit vs epirubicin monotherapy in advanced soft tissue sarcoma.

Trispecific Antibody JNJ-5322 Shows Potential to Redefine Treatment in R/R Multiple Myeloma

August 18th 2025

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, details the rationale for evaluating the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.

Dr Mewawalla on Unmet Needs After Early CAR T-Cell Therapy in Relapsed/Refractory Myeloma

August 18th 2025

Prerna Mewawalla, MD, discusses needs that remain to be addressed in patients with relapsed/refractory myeloma who receive earlier-line CAR T-cell therapy.